Endogenous and radiation-induced expression of γH2AX in biopsies from patients treated for carcinoma of the uterine cervix
Received 15 July 2009; received in revised form 1 October 2009; accepted 14 October 2009. published online 11 November 2009.
Abstract
Background and purpose
The possibility of using γH2AX foci as a marker of DNA damage and as a potential predictor of tumour response to treatment was examined using biopsies from 3 sets of patients with advanced carcinoma of the cervix. The relation between endogenous γH2AX expression and hypoxia was also examined.
Materials and methods
Set 1 consisted of 26 biopsies that included pre-treatment and 24h post-radiation treatment samples. Pre-treatment biopsies from 12 patients in Set 2 were used to develop image analysis software while pre-treatment biopsies from 33 patients in Set 3 were examined for the relation between staining for the hypoxia marker pimonidazole and endogenous γH2AX expression. Formalin-fixed paraffin-embedded sections were analyzed after antigen retrieval and fluorescence antibody labeling for the hypoxia markers CAIX or pimonidazole in combination with γH2AX staining.
Results
Before treatment, 24±19% of cells contained γH2AX foci, with most positive cells containing fewer than 5 foci per nucleus. Twenty-four hours after exposure to the first fraction of 1.8–2.5Gy, 38±19% contained foci. CAIX positive cells were 1.4 times more likely to exhibit endogenous γH2AX foci, and pimonidazole-positive cells were 2.8 times more likely to contain γH2AX foci. For 18 patients for whom both pre-treatment and 24h post-irradiation biopsies were available, local control was unrelated to the fraction of cells that retained γH2AX foci. However, 24h after irradiation, tumours that had received 2.5Gy showed a significantly higher fraction of cells with residual γH2AX foci than tumours given 1.8Gy.
Conclusions
Endogenous γH2AX foci are enriched in hypoxic tumour regions. Small differences in delivered dose can produce quantifiable differences in residual DNA damage that can overshadow inter-tumour differences in response.
cBritish Columbia Cancer Agency, Vancouver Clinic, Vancouver, Canada
Corresponding author. Address: Medical Biophysics Department, British Columbia Cancer Agency Research Centre, 675 W. 10th Ave., Vancouver, BC, Canada V5Z 1L3.
ABSTRACT